These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37552426)

  • 1. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
    Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
    Suárez-García I; Alejos B; Hernando V; Viñuela L; Vera García M; Rial-Crestelo D; Pérez Elías MJ; Albendín Iglesias H; Peraire J; Tiraboschi J; Díaz A; Moreno S; Jarrín I;
    J Antimicrob Chemother; 2023 Jun; 78(6):1423-1432. PubMed ID: 37099559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF
    Zhang F; Wu H; Cai W; Ma P; Zhao Q; Wei H; Lu H; Wang H; He S; Chen Z; Chen Y; Wang M; Wan W; Fu H; Qin H
    Lancet Reg Health West Pac; 2024 Aug; 49():101143. PubMed ID: 39092318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan.
    Kanamori R; Aoki N; Kanazawa A; Nakamoto D; Yuda M; Makino N; Ohata E; Fukui N; Mori H; Yokokawa H; Naito T
    Front Med (Lausanne); 2024; 11():1329922. PubMed ID: 39318599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
    Rotea-Salvo S; Martínez-Pradeda A; Fernández-Oliveira C; Giménez-Arufe V; Balboa-Barreiro V; Margusino-Framiñán L; Mena-De-Cea Á; Vázquez-Rodríguez P; Castro-Iglesias Á; López-Calvo S; Martín-Herranz I; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2023 Jul; 30(4):221-226. PubMed ID: 34649965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016.
    Perez Valero I; Cabello A; Ryan P; De La Fuente-Moral S; Santos I; Vivancos MJ; Gonzalez A; Gorgolas M; Cuevas G; Diaz De Santiago A; Cano J; Rua G; Yllescas M; González García JJ
    Open Forum Infect Dis; 2020 Dec; 7(12):ofaa482. PubMed ID: 33335931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):T171-T175. PubMed ID: 38806363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
    Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
    AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
    McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
    Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
    Acosta RK; D'Antoni ML; Mulato A; Yant SR; Cihlar T; White KL
    Antimicrob Agents Chemother; 2022 May; 66(5):e0203821. PubMed ID: 35389236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
    Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabina/tenofovir-alafenamide among people with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):171-175. PubMed ID: 38448360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.
    Donga P; Emond B; Rossi C; Bookhart BK; Lee J; Caron-Lapointe G; Wei F; Lafeuille MH
    Clinicoecon Outcomes Res; 2023; 15():579-591. PubMed ID: 37521004
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.